AB SCIEX launches 3200MD CE-IVDD series in European countries for in vitro diagnostic use AB SCIEX.
The company has excelled at advancing and simplifying LC/MS/MS technology, so it is easier for laboratories to adopt and make use of for routine analysis. The robustness and simplicity of the 3200 products makes it a preferred instrument for study laboratories of all sizes. Now applying its expertise and experience to the IVD marketplace, AB SCIEX can be expanding its assistance offerings to supply enhanced support and provider designed for clinical diagnostics.. AB SCIEX launches 3200MD CE-IVDD series in European countries for in vitro diagnostic use AB SCIEX, a worldwide leader in analytical technologies, today announced the launch of the 3200MD CE-IVDD series for general in vitro diagnostic use in Europe.Related StoriesNew initiative launched to accelerate search for effective HIV vaccineGHIT Fund invests $10.7 million to combat malaria, TB, leishmaniasis and dengueResearchers reveal why malaria vaccine provides only moderate protection among vaccinated childrenThe research, which builds on previous studies that show web-based information has a positive influence on vaccine uptake, surveyed 179 parents. Those recruited to be a part of the analysis were first-time parents whose kids were offered the vaccine for the very first time from GPs surgeries in the North of England. Parents had been put into three groups: those that visited their GP and were provided with logon information to an MMR site by post, those that visited their GP and given an information leaflet, or those who just acquired a GP appointment.